Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies

INTRODUCTION: Tanezumab is a monoclonal antibody against nerve growth factor that is under investigation for the treatment of osteoarthritis (OA) pain. We conducted subgroup analyses of two randomized phase 3 studies to summarize efficacy, general safety, and adjudicated joint safety of tanezumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miki, Kenji, Ohta, Makoto, Abe, Manabu, Yoshimatsu, Hiroki, Fujii, Koichi, Ebata, Nozomi, West, Christine R., Brown, Mark T., Pixton, Glenn, Isogawa, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314481/
https://www.ncbi.nlm.nih.gov/pubmed/35538185
http://dx.doi.org/10.1007/s40122-022-00384-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314481/
https://www.ncbi.nlm.nih.gov/pubmed/35538185
http://dx.doi.org/10.1007/s40122-022-00384-y

Ejemplares similares